Nuo Therapeutics, Inc. (AURX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 1 | 1 | 3 | 5 | 6 |
| Operating profit | $m | -3 | -2 | ||||||
| Net profit | $m | -0 | -0 | -3 | -3 | -2 | -3 | -2 | -2 |
| EPS reported | $ | -0.05 | -0.04 | ||||||
| Operating cashflow per share | $ | -0.02 | -0.04 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -0.02 | -0.05 | ||||||
| Free cash flow | $m | -1 | -2 | ||||||
| Net debt | $m | -0 | 1 | ||||||
| Book value equity | $m | -1 | -2 | ||||||
| Book value per share | $ | -0.02 | -0.03 | ||||||
| Number of shares | m | 47.31 | 48.41 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -97.44 | -60.71 | ||||||
| P/S LTM | x | 28.13 | 17.92 | ||||||
| P/FCF LTM | x | -81.78 | -38.09 | ||||||
| EV/EBITDA LTM | x | -39.52 | -59.80 | ||||||
| EV/Sales LTM | x | 28.14 | 11.47 | ||||||
| Earnings Yield LTM | % | -2.70% | -3.44% | ||||||
| FCF Yield | % | -1.22% | -2.63% | ||||||
| Quality | |||||||||
| ROE | % | +262.63% | +187.41% | ||||||
| ROIC | % | -4.09% | -1.53% | ||||||
| Operating margin | % | -75.95% | -33.32% | ||||||
| Gross margin | % | +66.94% | +64.11% | ||||||
| FCF/Sales | % | -34.40% | -47.06% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +142.72% | +280.91% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.91 | -1.64 | ||||||
| Net Debt/EBITDA | x | -0.02 | -0.67 | ||||||
| EBIT/Net interest | x | -3,130.16 | -5.96 | ||||||
| Net debt/market cap | % | +0.54% | +2.55% | ||||||
| Net debt/Equity | x | 0.05 | -0.64 | ||||||
| Gross debt/equity | x | -0.62 | -0.97 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free